Center for Breast Cancer
Yale New Haven Hospital
20 York Street, Fl 1st, suite A
New Haven, CT 06510
- Center for Breast CancerYale New Haven Hospital20 York Street, Fl 1st, suite ANew Haven, CT 06510
Michael DiGiovanna, MD, PhD
Medical Oncology, Breast Oncology
Telehealth is available
Patient type treated
Adult
Accepting new patients
Yes
Referral required
From patients or physicians
Board Certified in
Internal Medicine and Medical Oncology
Biography
Michael DiGiovanna, MD, PhD, is a professor of internal medicine at Yale School of Medicine and, as a Yale Medicine oncologist, treats cancer patients at the Yale Cancer Center. His primary focus is the treatment and management of breast cancer.
Dr. DiGiovanna has conducted both clinical and laboratory-based research having led a translational laboratory focused on signal transduction in breast cancer. His research delves into breast cancer treatment strategies, including studies of targeted drug combinations for treating breast cancer. Dr. DiGiovanna’s work has been recognized with several awards and grants, including an American Cancer Society Research Scholar Grant and a Women's Health Investigator Award.
Titles
- Professor of Internal Medicine (Medical Oncology)
- Chair, Breast Cancer Tumor Board, Yale Cancer Center
- Curriculum Director, Office of Education
- Thread Leader, Pharmacology, Office of Education
- Master Course Co-Leader, Office of Education
Education & Training
- FellowYale School of Medicine (1997)
- Postdoctoral FellowYale University (1997)
- ResidentYale University School of Medicine (1994)
- PhDYale University (1990)
- MDYale University (1990)
- BACornell University, Biology (Biochemistry), Music (1984)
Additional Information
Honors & Recognitions
- Alvan R. Feinstein Award: Yale School of Medicine (2019)
- Swebilius Translational Cancer Research Award: Yale University (2006)
- Women's Health Investigator Award: Ethel F. Donaghue Women's Health Investigator Program at Yale (2005)
- American Cancer Society Research Scholar Grant: American Cancer Society (2002)
- Angel of Hope Award: American Cancer Society (2002)
- Career Development Award: US Army Medical Research & Materiel Command Department of Defense (1997)
- Hoffman-La Roche Travel Award: American Association for Cancer Research (1996)
- Postdoctoral Fellowship Award: US Army Medical Research & Development Command Department of Defense (1994)
Professional Service
- Yale Department of Medicine, Search committee for Chief of Geriatrics (2019 - 2020): Search committee for Chief of Geriatrics
- Yale Medical Oncology, Retreat Planning Committee (2019 - 2020): Planning committee for section retreat
- Search Committee for Geriatrics Section Chief, YSM (2019 - Present): Search Committee for Geriatrics Section Chief
- Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2018 (2018): Presenter for meeting review; Hosted by Yale, attended by regional audience
- JCO Precision Oncology (2018 - Present): Reviewer
- Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2017 (2017): Meeting review; Hosted by Yale, attended by regional audience
- Education Policy and Curriculum Committee, YSM (2016 - Present): As a YSM curriculum director, I serve on the EPCC which oversees all of medical education
- Integrated Courses Review Committee, YSM (2015 - Present): Chair
- Course Directors Meetings (2015 - Present): As Co-Director of the Pre-Clerkship Curriculum for YSM, I co-chair this monthly meeting of all YSM course and thread leaders
- Genes & Development Master Course, YSM (2015 - Present): Co-Leader of one of eight "Master Courses" that constitute the YSM pre-clerkship curriculum
Publications
- Kahn A, Marczyk M, Silber A, Rozenblit M, Sanft T, DiGiovanna M, Schellhorn S, Krop I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. DOI: 10.1200/jco.2023.41.16_suppl.e18855.
- Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases. JAMA Oncology 2023, 9: 197-205. PMID: 36454580, PMCID: PMC9716438, DOI: 10.1001/jamaoncol.2022.5610.
- Greil R, Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB). Geburtshilfe Und Frauenheilkunde 2022, 82: e4-e5. DOI: 10.1055/s-0042-1746156.
- Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB). Cancer Research 2022, 82: pd4-04-pd4-04. DOI: 10.1158/1538-7445.sabcs21-pd4-04.
- Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.
- Mamounas EP, Untch M, Mano MS, Huang C, Geyer CE, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Annals Of Oncology 2021, 32: 1005-1014. PMID: 33932503, DOI: 10.1016/j.annonc.2021.04.011.
- Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.
- Lin N, Murthy R, Anders C, Borges V, Hurvitz S, Loi S, Abramson V, Bedard P, Oliveira M, Zelnack A, DiGiovanna M, Bachelot T, Chien A, O’Regan R, Wardley A, Mueller V, Carey L, McGoldrick S, An X, Winer E. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). Neuro-Oncology Advances 2020, 2: ii11-ii11. PMCID: PMC7401403, DOI: 10.1093/noajnl/vdaa073.041.
- Lin N, Murthy R, Anders C, Borges V, Hurvitz S, Loi S, Abramson V, Bedard P, Oliveira M, Zelnak A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, Müller V, Carey L, McGoldrick S, An G, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1005-1005. DOI: 10.1200/jco.2020.38.15_suppl.1005.
- Mano M, Loibl S, Mamounas E, von Minckwitz G, Huang C, Untch M, Wolmark N, Wapnir I, Yang Y, Conlin A, Kümmel S, Saghatchian M, DiGiovanna M, Strunk C, Zimovjanova M, Song C, Liu H, Tesarowski D, Blotner S, Lam L, Smitt M, Geyer C. Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. Cancer Research 2020, 80: p3-14-01-p3-14-01. DOI: 10.1158/1538-7445.sabcs19-p3-14-01.
- Kunst N, Wang S, Hood A, Mougalian S, DiGiovanna M, Adelson K, Pusztai L. Abstract PD10-05: Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer. Cancer Research 2020, 80: pd10-05-pd10-05. DOI: 10.1158/1538-7445.sabcs19-pd10-05.
- Abu-Khalaf M, Aderhold K, Marczyk M, Chung G, Hofstatter E, Sanft T, Silber A, DiGiovanna M, Zelterman D, Puzstai L, Hatzis C. Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25). Cancer Research 2020, 80: p5-13-02-p5-13-02. DOI: 10.1158/1538-7445.sabcs19-p5-13-02.
- Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.
- Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.
- Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.
- Levinsohn E, DiGiovanna M, Encandela J, Takizawa P, Hafler J, Lee A. A Novel Approach to the Medical Student Hematology Curriculum. Blood 2016, 128: 3537. DOI: 10.1182/blood.v128.22.3537.3537.
- Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.
- Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study. Cancer Research 2016, 76: p5-11-03-p5-11-03. DOI: 10.1158/1538-7445.sabcs15-p5-11-03.
- Gnanajothy R, Chung G, DiGiovanna M, Abu-Khalaf M, Lannin D, Harris L. Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH). Journal Of Clinical Oncology 2015, 33: 144-144. DOI: 10.1200/jco.2015.33.28_suppl.144.
- Yushak M, Bouberhan S, Han G, Epstein L, Mougalian S, Abu-Khalaf M, Chung G, DiGiovanna M, Sanft T, Pusztai L, Hofstatter E. Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing. 2015, 3879-3879. DOI: 10.1158/1538-7445.am2015-3879.
- Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Gershkovich P, Hatzis C, Pusztai L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. DOI: 10.1200/jco.2015.33.15_suppl.e12564.
- Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.
- Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Hofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A. Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United States. Cancer Research 2013, 73: p5-13-05-p5-13-05. DOI: 10.1158/0008-5472.sabcs13-p5-13-05.
- Mougalian S, Abu-Khalaf M, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States. Cancer Research 2013, 73: p3-14-02-p3-14-02. DOI: 10.1158/0008-5472.sabcs13-p3-14-02.
- Abu-Khalaf M, Hatzis C, Chung G, DiGiovanna M, Tara S, Erin H, Lajos P, James Y, Veronica C. Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience. Cancer Research 2013, 73: p6-11-03-p6-11-03. DOI: 10.1158/0008-5472.sabcs13-p6-11-03.
- Hatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes. Cancer Research 2013, 73: p6-06-37-p6-06-37. DOI: 10.1158/0008-5472.sabcs13-p6-06-37.
- Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction? Cancer Research 2013, 73: p6-06-09-p6-06-09. DOI: 10.1158/0008-5472.sabcs13-p6-06-09.
- Bulloch K, Irwin M, Chagpar A, Horowitz N, Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. DOI: 10.1200/jco.2013.31.26_suppl.124.
- James E, Chung G, Sowers N, Clark M, Lilian R, Abraham G, Chmael S, Cappiello M, DiGiovanna M, Hofstatter E, Sanft T, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.26_suppl.154.
- Brown J, Lannin D, Killelea B, DiGiovanna M, Rimm D. Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2013, 31: 1085-1085. DOI: 10.1200/jco.2013.31.15_suppl.1085.
- Sinclair N, Sakr B, Abu-Khalaf M, Somlo G, Black R, Chung G, Rizack T, Strenger R, Fenton M, DiGiovanna M, Constantinou M, Lannin D, Legare R, Chagpar A, Sambandam S, Bossuyt V, Rosati K, Harris L, Sikov W. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study. Journal Of Clinical Oncology 2013, 31: 619-619. DOI: 10.1200/jco.2013.31.15_suppl.619.
- James E, Chung G, DiGiovanna M, Sanft T, Hofstatter E, Sowers N, Clark M, Lilian R, Chmael S, Cappiello M, Abraham G, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 2587-2587. DOI: 10.1200/jco.2013.31.15_suppl.2587.
- Sinclair N, Abu-Khalaf M, Rizack T, Rosati K, Chung G, Legare R, DiGiovanna M, Fenton M, Bossuyt V, Strenger R, Sakr B, Lannin D, Gass J, Harris L, Sikov W. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. Journal Of Clinical Oncology 2012, 30: 1045-1045. DOI: 10.1200/jco.2012.30.15_suppl.1045.
- Abu-Khalaf M, Kim T, Chung G, DiGiovanna M, Radke S, Cornfeld D, Harris L. A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in for advanced breast cancer (BC). Journal Of Clinical Oncology 2011, 29: e13609-e13609. DOI: 10.1200/jco.2011.29.15_suppl.e13609.
- Offor O, Sullivan C, Rodov S, Lezon-Geyda K, Zerillo C, DiGiovanna M, Harris L. Abstract P6-15-09: Insulin-Like Growth Factor Receptor I (IGF1R) Inhibitors May Be Synergistic with Chemotherapy in Basal Breast Cancer. Cancer Research 2010, 70: p6-15-09-p6-15-09. DOI: 10.1158/0008-5472.sabcs10-p6-15-09.
- Abu-Khalaf M, Chung G, DiGiovanna M, Fishbach N, Zelterman D, Tuck D, Harris L. Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H Based Therapy: Safety and Pharmacodynamic (PD) Results. Cancer Research 2010, 70: p3-14-17-p3-14-17. DOI: 10.1158/0008-5472.sabcs10-p3-14-17.
- Abu-Khalaf M, Gettinger S, Trieu V, Deshpande H, DiGiovanna M, Azodi M, Desai N, Kelly W, Schwartz P, Harris L. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). Journal Of Clinical Oncology 2010, 28: 2534-2534. DOI: 10.1200/jco.2010.28.15_suppl.2534.
- Schulman-Green D, Ercolano E, McCorkle R, Bradley E, Prigerson H, Knobf T, DiGiovanna M, Quinn T, Dixon J. Initial Development and Content Validation of the Knowledge of Care Options (KOCO) Instrument (744). Journal Of Pain And Symptom Management 2010, 39: 446. DOI: 10.1016/j.jpainsymman.2009.11.225.
- Schwartz J, Christy C, Grube B, Rishi M, Tavassoli F, Bossuyt V, Harris L, DiGiovanna M, Lannin D. Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology. Journal Of Clinical Oncology 2009, 27: 633-633. DOI: 10.1200/jco.2009.27.15_suppl.633.
- Christy C, Rishi M, Schwartz J, Grube B, Bossuyt V, Philpotts L, DiGiovanna M, Tavassoli F, Lannin D. Association between HER2/neu overexpression and calcifications in breast cancer. Journal Of Clinical Oncology 2009, 27: 579-579. DOI: 10.1200/jco.2009.27.15_suppl.579.
- Mayer T, Harris L, DiGiovanna M. Drugs targeting insulin-like growth factor 1 receptor. Breast Cancer Online 2009, 12 DOI: 10.1017/s1470903109990058.
- Abu-Khalaf M, Kim R, Cohenuram M, Chung G, Digiovanna M, Haffty B, Carter D, Horvath L, Tavassoli F, Burtness B. Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC). Journal Of Clinical Oncology 2006, 24: 10721-10721. DOI: 10.1200/jco.2006.24.18_suppl.10721.
- DiGiovanna M, Stern D, Edgerton S, Thor A. In Reply:. Journal Of Clinical Oncology 2005, 23: 8119-8120. DOI: 10.1200/jco.2005.03.2318.
- Claus E, Chu P, Howe C, Davison T, Stern D, Carter D, DiGiovanna M. Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors. Experimental And Molecular Pathology 2001, 70: 303-316. PMID: 11418009, DOI: 10.1006/exmp.2001.2366.
- Khan A, DiGiovanna M, Ross D, Sasaki C, Carter D, Son Y, Haffty B. Adenoid cystic carcinoma: A retrospective clinical review. International Journal Of Cancer 2001, 96: 149-158. PMID: 11410883, DOI: 10.1002/ijc.1013.
- DiGiovanna M. Commentary: Extracting functional information from tissues. Molecular Diagnosis 2001, 6: 13-15. DOI: 10.1054/modi.2001.21896.
- DiGiovanna M. Extracting Functional Information From Tissues. Molecular Diagnosis 2001, 6: 13-15. PMID: 11257207, DOI: 10.1007/bf03262099.
- DiGiovanna M, Roussel R, Stern D. Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides. Current Protocols In Molecular Biology 2000, 50: 18.6.1-18.6.19. PMID: 18265171, DOI: 10.1002/0471142727.mb1806s50.
- DiGiovanna M. Phosphorylation Sensitivity of the Commonly Used Anti-p185neu/erbB2Monoclonal Antibody Clone 3B5 Suggests Selective Usage of Autophosphorylation Sites. Analytical Biochemistry 1997, 247: 167-170. PMID: 9126388, DOI: 10.1006/abio.1997.9919.
- DiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.
- DiGiovanna M, Sartorelli A. Differentiation stage specificity of tyrosine phosphorylation in response to granulocyte macrophage colony stimulating factor (GM-CSF). Cancer Letters 1992, 63: 15-22. PMID: 1555204, DOI: 10.1016/0304-3835(92)90084-9.
Departments and Programs
Locations
Center for Breast Cancer
Yale New Haven Hospital
20 York Street, Fl 1st, suite A
New Haven, CT 06510
- Center for Breast CancerYale New Haven Hospital20 York Street, Fl 1st, suite ANew Haven, CT 06510
Biography
Michael DiGiovanna, MD, PhD, is a professor of internal medicine at Yale School of Medicine and, as a Yale Medicine oncologist, treats cancer patients at the Yale Cancer Center. His primary focus is the treatment and management of breast cancer.
Dr. DiGiovanna has conducted both clinical and laboratory-based research having led a translational laboratory focused on signal transduction in breast cancer. His research delves into breast cancer treatment strategies, including studies of targeted drug combinations for treating breast cancer. Dr. DiGiovanna’s work has been recognized with several awards and grants, including an American Cancer Society Research Scholar Grant and a Women's Health Investigator Award.
Titles
- Professor of Internal Medicine (Medical Oncology)
- Chair, Breast Cancer Tumor Board, Yale Cancer Center
- Curriculum Director, Office of Education
- Thread Leader, Pharmacology, Office of Education
- Master Course Co-Leader, Office of Education
Education & Training
- FellowYale School of Medicine (1997)
- Postdoctoral FellowYale University (1997)
- ResidentYale University School of Medicine (1994)
- PhDYale University (1990)
- MDYale University (1990)
- BACornell University, Biology (Biochemistry), Music (1984)
Additional Information
Honors & Recognitions
- Alvan R. Feinstein Award: Yale School of Medicine (2019)
- Swebilius Translational Cancer Research Award: Yale University (2006)
- Women's Health Investigator Award: Ethel F. Donaghue Women's Health Investigator Program at Yale (2005)
- American Cancer Society Research Scholar Grant: American Cancer Society (2002)
- Angel of Hope Award: American Cancer Society (2002)
- Career Development Award: US Army Medical Research & Materiel Command Department of Defense (1997)
- Hoffman-La Roche Travel Award: American Association for Cancer Research (1996)
- Postdoctoral Fellowship Award: US Army Medical Research & Development Command Department of Defense (1994)
Professional Service
- Yale Department of Medicine, Search committee for Chief of Geriatrics (2019 - 2020): Search committee for Chief of Geriatrics
- Yale Medical Oncology, Retreat Planning Committee (2019 - 2020): Planning committee for section retreat
- Search Committee for Geriatrics Section Chief, YSM (2019 - Present): Search Committee for Geriatrics Section Chief
- Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2018 (2018): Presenter for meeting review; Hosted by Yale, attended by regional audience
- JCO Precision Oncology (2018 - Present): Reviewer
- Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven ASCO Review 2017 (2017): Meeting review; Hosted by Yale, attended by regional audience
- Education Policy and Curriculum Committee, YSM (2016 - Present): As a YSM curriculum director, I serve on the EPCC which oversees all of medical education
- Integrated Courses Review Committee, YSM (2015 - Present): Chair
- Course Directors Meetings (2015 - Present): As Co-Director of the Pre-Clerkship Curriculum for YSM, I co-chair this monthly meeting of all YSM course and thread leaders
- Genes & Development Master Course, YSM (2015 - Present): Co-Leader of one of eight "Master Courses" that constitute the YSM pre-clerkship curriculum
Publications
- Kahn A, Marczyk M, Silber A, Rozenblit M, Sanft T, DiGiovanna M, Schellhorn S, Krop I, Lustberg M, Winer E, Pusztai L. Trends in breast cancer death by stage at diagnoses in 2000-2018. Journal Of Clinical Oncology 2023, 41: e18855-e18855. DOI: 10.1200/jco.2023.41.16_suppl.e18855.
- Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases. JAMA Oncology 2023, 9: 197-205. PMID: 36454580, PMCID: PMC9716438, DOI: 10.1001/jamaoncol.2022.5610.
- Greil R, Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Aktualisierte Ergebnisse von Tucatinib versus Placebo in Kombination mit Trastuzumab und Capecitabin bei Patienten mit vorbehandeltem, metastasierten HER2-positiven Brustkrebs mit ZNS-Metastasen (HER2CLIMB). Geburtshilfe Und Frauenheilkunde 2022, 82: e4-e5. DOI: 10.1055/s-0042-1746156.
- Lin N, Murthy R, Abramson V, Anders C, Bachelot T, Bedard P, Borges V, Cameron D, Cameron D, Carey L, Chien A, Curigliano G, DiGiovanna M, Gelmon K, Hortobagyi G, Hurvitz S, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB). Cancer Research 2022, 82: pd4-04-pd4-04. DOI: 10.1158/1538-7445.sabcs21-pd4-04.
- Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.
- Mamounas EP, Untch M, Mano MS, Huang C, Geyer CE, von Minckwitz G, Wolmark N, Pivot X, Kuemmel S, DiGiovanna MP, Kaufman B, Kunz G, Conlin AK, Alcedo JC, Kuehn T, Wapnir I, Fontana A, Hackmann J, Polikoff J, Saghatchian M, Brufsky A, Yang Y, Zimovjanova M, Boulet T, Liu H, Tesarowski D, Lam LH, Song C, Smitt M, Loibl S. Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Annals Of Oncology 2021, 32: 1005-1014. PMID: 33932503, DOI: 10.1016/j.annonc.2021.04.011.
- Kunst N, Wang SY, Hood A, Mougalian SS, DiGiovanna MP, Adelson K, Pusztai L. Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer. JAMA Network Open 2020, 3: e2027074. PMID: 33226431, PMCID: PMC7684449, DOI: 10.1001/jamanetworkopen.2020.27074.
- Lin N, Murthy R, Anders C, Borges V, Hurvitz S, Loi S, Abramson V, Bedard P, Oliveira M, Zelnack A, DiGiovanna M, Bachelot T, Chien A, O’Regan R, Wardley A, Mueller V, Carey L, McGoldrick S, An X, Winer E. 53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB). Neuro-Oncology Advances 2020, 2: ii11-ii11. PMCID: PMC7401403, DOI: 10.1093/noajnl/vdaa073.041.
- Lin N, Murthy R, Anders C, Borges V, Hurvitz S, Loi S, Abramson V, Bedard P, Oliveira M, Zelnak A, DiGiovanna M, Bachelot T, Chien A, O'Regan R, Wardley A, Müller V, Carey L, McGoldrick S, An G, Winer E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB). Journal Of Clinical Oncology 2020, 38: 1005-1005. DOI: 10.1200/jco.2020.38.15_suppl.1005.
- Mano M, Loibl S, Mamounas E, von Minckwitz G, Huang C, Untch M, Wolmark N, Wapnir I, Yang Y, Conlin A, Kümmel S, Saghatchian M, DiGiovanna M, Strunk C, Zimovjanova M, Song C, Liu H, Tesarowski D, Blotner S, Lam L, Smitt M, Geyer C. Abstract P3-14-01: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: KATHERINE subgroup analysis. Cancer Research 2020, 80: p3-14-01-p3-14-01. DOI: 10.1158/1538-7445.sabcs19-p3-14-01.
- Kunst N, Wang S, Hood A, Mougalian S, DiGiovanna M, Adelson K, Pusztai L. Abstract PD10-05: Cost-effectiveness of different neoadjuvant followed by adjuvant treatment combination strategies for women with HER2-positive breast cancer. Cancer Research 2020, 80: pd10-05-pd10-05. DOI: 10.1158/1538-7445.sabcs19-pd10-05.
- Abu-Khalaf M, Aderhold K, Marczyk M, Chung G, Hofstatter E, Sanft T, Silber A, DiGiovanna M, Zelterman D, Puzstai L, Hatzis C. Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25). Cancer Research 2020, 80: p5-13-02-p5-13-02. DOI: 10.1158/1538-7445.sabcs19-p5-13-02.
- Pusztai L, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, DiGiovanna M, Frederick C, Burello T, Harigopal M. Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC). Journal Of Clinical Oncology 2018, 36: 586-586. DOI: 10.1200/jco.2018.36.15_suppl.586.
- Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.
- Pusztai L, Silber A, Hofstatter E, Chung G, Horowitz N, Lannin D, Killelea B, Chagpar A, Szekely B, Frederick C, Rispoli L, DiGiovanna M. Safety of MEDI4736 (anti-PD-L1 antibody) administered concomitant with weekly nab-paclitaxel and dose dense doxorubicin/cyclophosphamide (ddAC) as neoadjuvant chemotherapy for stage I-III triple negative breast cancer (TNBC): A Phase I/II trial. Journal Of Clinical Oncology 2017, 35: 572-572. DOI: 10.1200/jco.2017.35.15_suppl.572.
- Levinsohn E, DiGiovanna M, Encandela J, Takizawa P, Hafler J, Lee A. A Novel Approach to the Medical Student Hematology Curriculum. Blood 2016, 128: 3537. DOI: 10.1182/blood.v128.22.3537.3537.
- Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Gross C, Pusztai L, Mougalian S. Onset of side effects and adherence to endocrine therapy in the Breast Cancer Endocrine Therapy Adherence (BETA) pilot study. Journal Of Clinical Oncology 2016, 34: e18136-e18136. DOI: 10.1200/jco.2016.34.15_suppl.e18136.
- Epstein L, Jhaveri A, Han G, Abu-Khalaf M, Hofstatter E, Sanft T, DiGiovanna M, Silber A, Adelson K, Chung G, Pusztai L, Gross C, Mougalian S. Abstract P5-11-03: Development of an interactive text messaging tool to improve adherence with adjuvant endocrine therapy: Breast cancer endocrine therapy adherence (BETA) pilot study. Cancer Research 2016, 76: p5-11-03-p5-11-03. DOI: 10.1158/1538-7445.sabcs15-p5-11-03.
- Gnanajothy R, Chung G, DiGiovanna M, Abu-Khalaf M, Lannin D, Harris L. Review of trends in adjuvant chemotherapy regimens in breast cancer over 10 year period at Yale New Haven Hospital (YNHH). Journal Of Clinical Oncology 2015, 33: 144-144. DOI: 10.1200/jco.2015.33.28_suppl.144.
- Yushak M, Bouberhan S, Han G, Epstein L, Mougalian S, Abu-Khalaf M, Chung G, DiGiovanna M, Sanft T, Pusztai L, Hofstatter E. Abstract 3879: Patient preferences for disclosure of incidental genetic information discovered through high-throughput sequencing. 2015, 3879-3879. DOI: 10.1158/1538-7445.am2015-3879.
- Patel J, Reiner E, Bossuyt V, Epstein L, Platt J, DiGiovanna M, Chung G, Silber A, Sanft T, Hofstatter E, Mougalian S, Abu-Khalaf M, Gershkovich P, Hatzis C, Pusztai L. Mutation-based treatment recommendations from next generation sequencing data: A comparison of web tools. Journal Of Clinical Oncology 2015, 33: e12564-e12564. DOI: 10.1200/jco.2015.33.15_suppl.e12564.
- Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective study of the decision-making impact of the Breast Cancer Index in the selection of patients with ER+ breast cancer for extended endocrine therapy. Journal Of Clinical Oncology 2015, 33: 538-538. DOI: 10.1200/jco.2015.33.15_suppl.538.
- Jhaveri A, Abu-Khalaf M, DiGiovanna M, Pusztai L, Hofstatter E, Sanft T, Sowers N, Lurie B, Silber A, Brandt D, Hochster H, Lacy J, Stein S, Chung G. Pilot study of sorafenib and biweekly capecitabine in patients with advanced breast and gastrointestinal tumors. Journal Of Clinical Oncology 2014, 32: 2561-2561. DOI: 10.1200/jco.2014.32.15_suppl.2561.
- Hofstatter E, Lannin D, Horowitz N, Killelea B, Tsangaris T, Pusztai L, Chung G, Sanft T, DiGiovanna M, AbuKhalaf M, Mougalian S, Chagpar A. Abstract P5-13-05: Richer and wiser: Factors correlated with chemoprevention use in the United States. Cancer Research 2013, 73: p5-13-05-p5-13-05. DOI: 10.1158/0008-5472.sabcs13-p5-13-05.
- Mougalian S, Abu-Khalaf M, Sanft T, Hofstatter E, DiGiovanna M, Chung G, Lannin D, Killelea B, Pusztai L, Chagpar A. Abstract P3-14-02: Patterns of the use of primary systemic therapy in the United States. Cancer Research 2013, 73: p3-14-02-p3-14-02. DOI: 10.1158/0008-5472.sabcs13-p3-14-02.
- Abu-Khalaf M, Hatzis C, Chung G, DiGiovanna M, Tara S, Erin H, Lajos P, James Y, Veronica C. Abstract P6-11-03: Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience. Cancer Research 2013, 73: p6-11-03-p6-11-03. DOI: 10.1158/0008-5472.sabcs13-p6-11-03.
- Hatzis C, Gould R, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans W, Pusztai L. Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes. Cancer Research 2013, 73: p6-06-37-p6-06-37. DOI: 10.1158/0008-5472.sabcs13-p6-06-37.
- Abu-Khalaf M, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Abstract P6-06-09: Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction? Cancer Research 2013, 73: p6-06-09-p6-06-09. DOI: 10.1158/0008-5472.sabcs13-p6-06-09.
- Bulloch K, Irwin M, Chagpar A, Horowitz N, Killelea B, Pusztai L, Abu-Khalaf M, DiGiovanna M, Chung G, Hofstatter E, Levy A, Sanft T. The impact of survivorship care plans on knowledge among breast cancer survivors. Journal Of Clinical Oncology 2013, 31: 124-124. DOI: 10.1200/jco.2013.31.26_suppl.124.
- James E, Chung G, Sowers N, Clark M, Lilian R, Abraham G, Chmael S, Cappiello M, DiGiovanna M, Hofstatter E, Sanft T, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 154-154. DOI: 10.1200/jco.2013.31.26_suppl.154.
- Brown J, Lannin D, Killelea B, DiGiovanna M, Rimm D. Quantitative Ki-67 score as predictive of response to neoadjuvant chemotherapy in breast cancer. Journal Of Clinical Oncology 2013, 31: 1085-1085. DOI: 10.1200/jco.2013.31.15_suppl.1085.
- Sinclair N, Sakr B, Abu-Khalaf M, Somlo G, Black R, Chung G, Rizack T, Strenger R, Fenton M, DiGiovanna M, Constantinou M, Lannin D, Legare R, Chagpar A, Sambandam S, Bossuyt V, Rosati K, Harris L, Sikov W. Multicenter phase II trial of neoadjuvant carboplatin, weekly nab-paclitaxel, and trastuzumab in stage II-III HER2+ breast cancer: A BrUOG study. Journal Of Clinical Oncology 2013, 31: 619-619. DOI: 10.1200/jco.2013.31.15_suppl.619.
- James E, Chung G, DiGiovanna M, Sanft T, Hofstatter E, Sowers N, Clark M, Lilian R, Chmael S, Cappiello M, Abraham G, Israel G, Pusztai L, Harris L, Abu-Khalaf M. Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer. Journal Of Clinical Oncology 2013, 31: 2587-2587. DOI: 10.1200/jco.2013.31.15_suppl.2587.
- Sinclair N, Abu-Khalaf M, Rizack T, Rosati K, Chung G, Legare R, DiGiovanna M, Fenton M, Bossuyt V, Strenger R, Sakr B, Lannin D, Gass J, Harris L, Sikov W. Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study. Journal Of Clinical Oncology 2012, 30: 1045-1045. DOI: 10.1200/jco.2012.30.15_suppl.1045.
- Abu-Khalaf M, Kim T, Chung G, DiGiovanna M, Radke S, Cornfeld D, Harris L. A phase I study of biweekly capecitabine and the histone deacetylase inhibitors (HDACi) vorinostat in for advanced breast cancer (BC). Journal Of Clinical Oncology 2011, 29: e13609-e13609. DOI: 10.1200/jco.2011.29.15_suppl.e13609.
- Offor O, Sullivan C, Rodov S, Lezon-Geyda K, Zerillo C, DiGiovanna M, Harris L. Abstract P6-15-09: Insulin-Like Growth Factor Receptor I (IGF1R) Inhibitors May Be Synergistic with Chemotherapy in Basal Breast Cancer. Cancer Research 2010, 70: p6-15-09-p6-15-09. DOI: 10.1158/0008-5472.sabcs10-p6-15-09.
- Abu-Khalaf M, Chung G, DiGiovanna M, Fishbach N, Zelterman D, Tuck D, Harris L. Abstract P3-14-17: Trastuzumab (H) and Rapamycin (R) for Treatment of HER-2 Overexpressing Metastatic Breast Cancer (BC) with Prior Disease Progression on H Based Therapy: Safety and Pharmacodynamic (PD) Results. Cancer Research 2010, 70: p3-14-17-p3-14-17. DOI: 10.1158/0008-5472.sabcs10-p3-14-17.
- Abu-Khalaf M, Gettinger S, Trieu V, Deshpande H, DiGiovanna M, Azodi M, Desai N, Kelly W, Schwartz P, Harris L. A phase I study of the mTOR inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel (nab-P). Journal Of Clinical Oncology 2010, 28: 2534-2534. DOI: 10.1200/jco.2010.28.15_suppl.2534.
- Schulman-Green D, Ercolano E, McCorkle R, Bradley E, Prigerson H, Knobf T, DiGiovanna M, Quinn T, Dixon J. Initial Development and Content Validation of the Knowledge of Care Options (KOCO) Instrument (744). Journal Of Pain And Symptom Management 2010, 39: 446. DOI: 10.1016/j.jpainsymman.2009.11.225.
- Schwartz J, Christy C, Grube B, Rishi M, Tavassoli F, Bossuyt V, Harris L, DiGiovanna M, Lannin D. Histologic subtypes of ductal intraepithelial neoplasia (DIN) of the breast: Characteristic associations and biology. Journal Of Clinical Oncology 2009, 27: 633-633. DOI: 10.1200/jco.2009.27.15_suppl.633.
- Christy C, Rishi M, Schwartz J, Grube B, Bossuyt V, Philpotts L, DiGiovanna M, Tavassoli F, Lannin D. Association between HER2/neu overexpression and calcifications in breast cancer. Journal Of Clinical Oncology 2009, 27: 579-579. DOI: 10.1200/jco.2009.27.15_suppl.579.
- Mayer T, Harris L, DiGiovanna M. Drugs targeting insulin-like growth factor 1 receptor. Breast Cancer Online 2009, 12 DOI: 10.1017/s1470903109990058.
- Abu-Khalaf M, Kim R, Cohenuram M, Chung G, Digiovanna M, Haffty B, Carter D, Horvath L, Tavassoli F, Burtness B. Neoadjuvant dose-dense (DD) concurrent doxorubicin (A) and docetaxel (T) for stage III breast cancer (BC). Journal Of Clinical Oncology 2006, 24: 10721-10721. DOI: 10.1200/jco.2006.24.18_suppl.10721.
- DiGiovanna M, Stern D, Edgerton S, Thor A. In Reply:. Journal Of Clinical Oncology 2005, 23: 8119-8120. DOI: 10.1200/jco.2005.03.2318.
- Claus E, Chu P, Howe C, Davison T, Stern D, Carter D, DiGiovanna M. Pathobiologic Findings in DCIS of the Breast: Morphologic Features, Angiogenesis, HER-2/neu and Hormone Receptors. Experimental And Molecular Pathology 2001, 70: 303-316. PMID: 11418009, DOI: 10.1006/exmp.2001.2366.
- Khan A, DiGiovanna M, Ross D, Sasaki C, Carter D, Son Y, Haffty B. Adenoid cystic carcinoma: A retrospective clinical review. International Journal Of Cancer 2001, 96: 149-158. PMID: 11410883, DOI: 10.1002/ijc.1013.
- DiGiovanna M. Commentary: Extracting functional information from tissues. Molecular Diagnosis 2001, 6: 13-15. DOI: 10.1054/modi.2001.21896.
- DiGiovanna M. Extracting Functional Information From Tissues. Molecular Diagnosis 2001, 6: 13-15. PMID: 11257207, DOI: 10.1007/bf03262099.
- DiGiovanna M, Roussel R, Stern D. Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides. Current Protocols In Molecular Biology 2000, 50: 18.6.1-18.6.19. PMID: 18265171, DOI: 10.1002/0471142727.mb1806s50.
- DiGiovanna M. Phosphorylation Sensitivity of the Commonly Used Anti-p185neu/erbB2Monoclonal Antibody Clone 3B5 Suggests Selective Usage of Autophosphorylation Sites. Analytical Biochemistry 1997, 247: 167-170. PMID: 9126388, DOI: 10.1006/abio.1997.9919.
- DiGiovanna M, Carter D, Flynn S, Stern D. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours. British Journal Of Cancer 1996, 74: 802-806. PMID: 8795585, PMCID: PMC2074709, DOI: 10.1038/bjc.1996.439.
- DiGiovanna M, Sartorelli A. Differentiation stage specificity of tyrosine phosphorylation in response to granulocyte macrophage colony stimulating factor (GM-CSF). Cancer Letters 1992, 63: 15-22. PMID: 1555204, DOI: 10.1016/0304-3835(92)90084-9.
Departments and Programs
Locations
Center for Breast Cancer
Yale New Haven Hospital
20 York Street, Fl 1st, suite A
New Haven, CT 06510
- Center for Breast CancerYale New Haven Hospital20 York Street, Fl 1st, suite ANew Haven, CT 06510
Center for Breast Cancer
Yale New Haven Hospital
20 York Street, Fl 1st, suite A
New Haven, CT 06510
- Center for Breast CancerYale New Haven Hospital20 York Street, Fl 1st, suite ANew Haven, CT 06510